跳至主要内容
临床试验/ACTRN12622000127707
ACTRN12622000127707尚未招募未知

Evaluating audit and feedback for reducing long-term prescribing of benzodiazepines and opioids by Australian general practitioners: a factorial cluster randomised trial

PS MedicineWise0 个研究点目标入组 30,000 人开始时间: 2022年1月27日最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
30,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Educational / counselling / training
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • General practitioners (GPs) and other medical practitioners (OMPs) practising in Australia. OMPs with a major speciality code of any of the following (as specified in MBS data dictionary, https://alswh.org.au/wp-content/uploads/2020/09/MBS_ALSWH_DataDictionary_2019.pdf) will be included:
  • 104 - Other non-specialist
  • 110 - Other non-specialist for nov 1996 - not elsewhere classified
  • 181 - TRD benefits not payable
  • 182 - TRD occupational trainee
  • 186 - Remote OMP
  • 188 - Medicare Plus pre 1996 OMP (restricted)
  • 189 - Medicare Plus pre 1996 OMP (un-restricted)
  • 196 - RRAPP
  • 199 - MDS After Hours OMP
  • 202 - Procedural GP - non-recognised
  • 615 - Outer metro OMP
  • Only targeted benzodiazepine and targeted opioid prescriptions that lead to a medicine being dispensed by a pharmacist and for which a Pharmaceutical Benefits Scheme (PBS) claim is made are in scope.

排除标准

  • 1. GPs with <160 MBS Category 1 consultations for the period 1 April 2021 to 30 June 2021.
  • 2. GPs who have opted-out of NPS MedicineWise Practice Reviews.
  • 3. GPs who have no primary/secondary/preferred mailing address or nominated email address.

研究者

发起方
PS MedicineWise

相似试验